TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19644228
Drug: Slow-titration group
Normalized name: Slow-Fe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-titration group (4 mg/24 h starting dose, increasing by 2 mg/24 h per week to a maximum of 24 mg/24 h)
Study: 2660250
Drug: Propranolol, 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol, 160 mg daily for 6 months (n = 15)
Study: 31897524
Drug: semaglutide 1.0
Normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 1.0 mg once weekly
Study: 31897524
Drug: canagliflozin 300
Normalized name: canagliflozin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: canagliflozin 300 mg once daily
Study: 22132950
Drug: Febuxostat (approved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (approved doses)
Study: 22132950
Drug: Allopurinol (commonly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (commonly prescribed doses)
Study: 19638331
Drug: L2 spinal
Normalized name: bovine spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L2 spinal nerve block (n = 30), 1.5 mL of 1% lidocaine
Study: 19638331
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection (control, n = 30), 1.5 mL of 1% lidocaine
Study: 1534287
Drug: Intravenous tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue-type plasminogen activator (t-PA)
Study: 11188774
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) treatment at a dose of 400 mg/kg bodyweight every 4 weeks
Study: 9277437
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of nutrients (protein, fat, carbohydrate) at 40, 90, and 160 kcal/h into the duodenum
Study: 9277437
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of more calories into the duodenum
Study: 8339523
Drug: 5-Fluorouracil 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-Fluorouracil 1000 mg/m2 and cis-platinum 20 mg/m2 for 5 consecutive days, with retinol palmitate at 15,000 IU b.i.d. in chemotherapy intervals
Study: 3089050
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% plain (20 ml)
Study: 3089050
Drug: Diamorphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diamorphine 2.5 mg in 10 ml normal saline
Study: 18354383
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor and calcium channel blocker
Study: 18354383
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor and thiazide diuretic
Study: 16061709
Drug: Pathogen directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogen directed treatment (PDT)
Study: 16061709
Drug: Empirical broad
Normalized name: broad leaved paperbark pollen extract
DrugBank: Melaleuca quinquenervia pollen (DB10478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical broad spectrum antibiotic treatment (EAT)
Study: 11919230
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens including bolus fluorouracil (5‐FU), 5‐FU and leucovorin, 5‐FU and levamisole, and 5‐FU, leucovorin, and levamisole followed by chemoradiation therapy (pelvic irradiation at 45 Gy with a boost to 50.4 to 54 Gy)
Study: 10652116
Drug: Sumatriptan 6
Normalized name: sumatriptan 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 6 mg (Imigran 0.5 mL)
Study: 8888372
Drug: CDP-choline (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDP-choline (single oral dose)
Study: 6289096
Drug: Cerebral gangliosides
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral gangliosides (50 mg once a day) for 40 days
Study: 18987553
Drug: Pyridostygmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostygmine (60 mg)
Study: 18987553
Drug: Bethanechol (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (25 mg)
Study: 18987553
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three agents (Pyridostygmine, Buspirone, Bethanechol)
Study: 16820420
Drug: ChEI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChEI treatment
Study: 10102256
Drug: Sibutramine 1
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 1 mg/day
Study: 8697058
Drug: Sibutramine 5
Normalized name: sibutramine 5 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 5 mg/day
Study: 8589555
Drug: Plasmatein (10%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmatein (10%, v/v; 5 mg/ml)
Study: 2317144
Drug: Endurance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurance training program (E) - three times weekly upper and lower conditioning program using target heart rates based on the symptom-limited exercise test (SLXT)
Study: 2317144
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C) - continued daily nursing home routine
Study: 347877
Drug: Bromperidol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromperidol (4 to 8 mg in one intake in the morning)
Study: 347877
Drug: Haloperidol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (4 mg given twice a day)
Study: 6122939
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of 5% dextrose in water (D5W) and 1000 ml normal saline (7.5 g dextrose)
Study: 6122939
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml of D5W, 350 ml of 5% dextrose in normal saline (D5NS), and 650 ml of normal saline (25 g dextrose)
Study: 6122939
Drug: 150 ml
Normalized name: REBYOTA 150 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 ml D5W and 1000 ml D5NS (57.5 g dextrose)
Study: 6122939
Drug: 57.5 g
Normalized name: GENTAMICIN SULFATE 8457.5 g in 8500 g NOT APPLICABLE POWDER [X]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 57.5 g of dextrose
Study: 17681972
Drug: Liberal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal fluid administration (median 5050 ml, range 3563-8050 ml)
Study: 17681972
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid administration (median 1640 ml, range 935-2250 ml)
Study: 7667959
Drug: Experimental diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental diet with topinambur (mashed topinambur 100 g/day and cookies with topinambur 50 g/day for 4 weeks)
Study: 2109195
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms four times daily for 12 weeks)
Study: 29576354
Drug: Aged garlic
Normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged garlic extract (AGE) 3.6 g daily for 6 weeks
Study: 1710742
Drug: Bezafibrate (Bezalip
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate (Bezalip Mono, 400 mg daily for 3 months)
Study: 361149
Drug: Bromocriptine, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine, 5 mg daily
Study: 26774526
Drug: PRO +
Normalized name: Climara Pro
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRO + FAT (micellar casein with 26.7 g milk fat)
Study: 18300900
Drug: External lumbar
Approvals — FDA: no, EMA: no, PMDA: no
Description: External lumbar drainage (ELD) of cerebrospinal fluid (approximately 135 mL/24 h for 3 days)
Study: 17136216
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg) and alcohol (1.0 mL 95% USP ethanol/kg body weight)
Study: 17136216
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and alcohol (1.0 mL 95% USP ethanol/kg body weight)
Study: 1475230
Drug: Enteric-coated 500-mg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated 500-mg naproxen tablets (fasted state)
Study: 1475230
Drug: Enteric-coated 500-mg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteric-coated 500-mg naproxen tablets (after breakfast)
Study: 25358330
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg loading dose of vancomycin
Study: 25358330
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg traditional dose of vancomycin
Study: 24617225
Drug: Medicine (dicetel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine (dicetel and bifidobacterium lactobacillus triple viable capsules)
Study: 21600128
Drug: Propofol 3
Normalized name: fospropofol 35 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 3 µg/ml plus remifentanil 2.5 ng/ml
Study: 21600128
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 µg/ml plus remifentanil 2.0 ng/ml
Study: 21600128
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 µg/ml plus remifentanil 3.0 ng/ml
Study: 18655554
Drug: Astragalus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus injection (40 mL, 10 mL containing 2 g of crude drug)
Study: 18655554
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Astragalus injection)
Study: 17068655
Drug: IntraSite Gel
Normalized name: Intrasite Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IntraSite Gel
Study: 10918470
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (4 glasses, 40 g alcohol/day)
Study: 10918470
Drug: Beer (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beer (4 glasses, 40 g alcohol/day)
Study: 10918470
Drug: Spirits (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirits (4 glasses, 40 g alcohol/day)
Study: 8157948
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy with enalapril (20-40 mg once a day)
Study: 8157948
Drug: Antihypertensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive therapy with enalapril
Study: 3145964
Drug: combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination of alpha-interferon and gamma-interferon
Study: 24977689
Drug: Oral stimulation
Normalized name: follicle stimulating hormone / luteinizing hormone Injection [Menopur]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral stimulation (OS)
Study: 31489639
Drug: Talazoparib 1
Normalized name: talazoparib 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 1 mg capsule
Study: 31489639
Drug: Talazoparib 0.75
Normalized name: talazoparib 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib 0.75 mg daily dose
Study: 20512414
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg entecavir daily until October 2009 (group A)
Study: 20512414
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg lamivudine daily until October 2009 (group B)
Study: 16078322
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy > 10 mg prednisolone equivalent per day
Study: 10636369
Drug: Third-generation oral
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Third-generation oral contraceptive (150 microg desogestrel and 30 microg ethinyloestradiol)
Study: 10636369
Drug: Second-generation oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-generation oral contraceptive (150 microg levonorgestrel and 30 microg ethinyloestradiol)
Study: 3873108
Drug: co‐trimoxazole (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐trimoxazole (800 mg sulphamethoxazole + 160 mg trimethoprim)
Study: 3873108
Drug: trimethoprim (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim (200 mg)
Study: 31204264
Drug: Low-Intensity Shockwave
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Intensity Shockwave Therapy (LiST)
Study: 27063317
Drug: Suggestion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suggestion therapy
Study: 15704046
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg orally for 14 days) plus calcium (500 mg daily) and vitamin D (400 IU daily) for 76 days, repeated 8 times over 24 months
Study: 15704046
Drug: Calcium (500
Normalized name: calcium gluconate 45 mg calcium (500 mg) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (500 mg daily) and vitamin D (400 IU daily) for 76 days, repeated 8 times over 24 months without etidronate
Study: 12081675
Drug: 100 U
Normalized name: vitamin E 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 U BTX‐A (50 U/ml/axilla)
Study: 8648964
Drug: Small dose
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small dose kaliposol + etomidate
Study: 8263318
Drug: Sertraline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (mean daily dose 72 mg)
Study: 8263318
Drug: Fluoxetine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (mean daily dose 28 mg)
Study: 4072939
Drug: Hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (50 or 100 mg/day)
Study: 4072939
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Diltiazem and Hydrochlorothiazide
Study: 30843453
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg THA
Study: 30843453
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg THA
Study: 29465273
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) antipsychotic delivery
Study: 22755270
Drug: 0.8 ml
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 ml of 4 mg 0.5% hyperbaric bupivacaine
Study: 22755270
Drug: 1.3-ml solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.3-ml solution of 4 mg 0.5% hyperbaric bupivacaine + 25 microg of fentanyl
Study: 22755270
Drug: 1.1-ml solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1-ml solution of 3 mg 0.5% hyperbaric bupivacaine + 25 microg of fentanyl
Study: 11818036
Drug: 3.5 hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 hour workshop on Evidence Based Medicine (EBM)
Study: 10367928
Drug: Tamponade treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamponade treatment
Study: 2076247
Drug: Sucrose-containing snacks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucrose-containing snacks (chocolate bar, cream-filled cupcakes, cream-filled sandwich cookie, cherry pie, raisins)
Study: 381221
Drug: Tolmetin 200
Normalized name: tolmetin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin 200 mg (T 200)
Study: 381221
Drug: Paracetamol 400
Normalized name: Hydrocodone bitartrate 5 mg and paracetamol 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 400 mg (P 400)
Study: 381221
Drug: Tolmetin 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin 150 mg plus Paracetamol 300 mg (T 150 + P 300)
Study: 381221
Drug: Tolmetin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolmetin 100 mg plus Paracetamol 400 mg (T 100 + P 400)
Study: 30404563
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (300 mg/day)
Study: 21885886
Drug: Moderate-to-vigorous intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-to-vigorous intensity exercise intervention for 6 months, home-based, telephone-administered
Study: 11254756
Drug: Simvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (40 mg/day for 30 days)
Study: 11254756
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) (600 mg/day for 30 days after a washout period)
Study: 8200250
Drug: Metronidazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (400 mg thrice daily for seven days)
Study: 20869152
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 25 mg
Study: 20869152
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 50 mg
Study: 20869152
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium liquid-filled soft gelatin capsule (DPSGC) 100 mg
Study: 19594501
Drug: Lithium monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium monotherapy (Phase 2)
Study: 6085377
Drug: Nitrendipine (10‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (10‐40 mg/day)
Study: 6085377
Drug: Hydralazine (50‐200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (50‐200 mg/day)
Study: 29159774
Drug: Rasagiline transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline transdermal patch (1.25 mg/24 h, 1.25 mg/48 h, 2.5 mg/48 h, 2.5 mg/72 h)
Study: 29159774
Drug: Rasagiline oral
Normalized name: rasagiline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline oral tablet (1 mg)
Study: 29159774
Drug: Rasagiline transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline transdermal patch (1.25 mg)
Study: 29159774
Drug: Rasagiline transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline transdermal patch (2.5 mg)
Study: 29159774
Drug: Rasagiline transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline transdermal patch (1.25-2.5 mg)
Study: 29159774
Drug: Rasagiline transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline transdermal patch
Study: 24004349
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplements (800 IU/day)
Study: 22296077
Drug: GAD‐alum (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD‐alum (four doses)
Study: 22296077
Drug: GAD‐alum (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD‐alum (two doses) followed by placebo (two doses)
Study: 2268811
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four doses)
Study: 22296077
Drug: GAD‐alum (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD‐alum (any dosage)
Study: 22296077
Drug: Placebo (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (any dosage)
Study: 18240797
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel composed of 18% potassium complex, 10% dimethylisosorbide, and 72% aqueous hydroxyethyl cellulose gel applied to the facial skin over painful areas.
Study: 18240797
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel application as a first-step procedure before definitive diagnosis and treatment.
Study: 18240797
Drug: Topical gel
Normalized name: Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gel application.
Study: 15900603
Drug: Imatinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib treatment followed by resection of residual disease
Study: 10519615
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg twice a day) for > or = 5 months
Study: 8522669
Drug: Enalaprilat 0.015
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat 0.015 mg kg‐1 injected within 5 min to 9 patients
Study: 1720527
Drug: MODE (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: MODE (at a mean concentration of 774 +/- 229 ng/ml)
Study: 6758935
Drug: Intravenous tiapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tiapamil (1 mg/kg loading dose followed by 50 micrograms/kg/min for 2 hours)
Study: 6758935
Drug: Oral tiapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tiapamil (approximately 6 mg/kg)
Study: 27396815
Drug: Programmed sports
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed sports therapy (PST)
Study: 24743431
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid (FA) 135 mg plus atorvastatin
Study: 24743431
Drug: Fenofibric acid
Normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibric acid (FA) plus atorvastatin
Study: 23809278
Drug: Levonorgestrel (LNG)
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levonorgestrel (LNG) 1.5 mg
Study: 10987677
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone substitution (2 IU/m2) for 12 months
Study: 7992358
Drug: Towne strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Towne strain attenuated CMV vaccine
Study: 49737
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (general relaxation)
Study: 27481122
Drug: Biological outcome
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological outcome variables
Study: 9291200
Drug: Usual-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-protein diet (1.3 g/kg/day)
Study: 9291200
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.58 g/kg/day)
Study: 9291200
Drug: Very-low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-low-protein diet (0.28 g/kg/day) supplemented with a ketoacid-amino acid mixture (0.28 g/kg/day)